Form 8-K - Current report:
SEC Accession No. 0001564590-20-006884
Filing Date
2020-02-27
Accepted
2020-02-26 18:21:13
Documents
13
Period of Report
2020-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acad-8k_20200226.htm   iXBRL 8-K 42584
2 EX-99.1 acad-ex991_6.htm EX-99.1 292110
  Complete submission text file 0001564590-20-006884.txt   479582

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acad-20200226.xsd EX-101.SCH 5984
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acad-20200226_lab.xml EX-101.LAB 19474
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acad-20200226_pre.xml EX-101.PRE 11642
12 EXTRACTED XBRL INSTANCE DOCUMENT acad-8k_20200226_htm.xml XML 3566
Mailing Address 3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO CA 92130 858-558-2871
ACADIA PHARMACEUTICALS INC (Filer) CIK: 0001070494 (see all company filings)

EIN.: 061376651 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50768 | Film No.: 20657682
SIC: 2834 Pharmaceutical Preparations